Workman Antony J, Pau Davide, Redpath Calum J, Marshall Gillian E, Russell Julie A, Kane Kathleen A, Norrie John, Rankin Andrew C
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, United Kingdom.
J Cardiovasc Electrophysiol. 2006 Nov;17(11):1230-8. doi: 10.1111/j.1540-8167.2006.00592.x.
We investigated whether post-cardiac surgery (CS) new-onset atrial fibrillation (AF) is predicted by pre-CS atrial cellular electrophysiology, and whether the antiarrhythmic effect of beta-blocker therapy may involve pre-CS pharmacological remodeling.
Atrial myocytes were obtained from consenting patients in sinus rhythm, just prior to CS. Action potentials and ion currents were recorded using whole-cell patch-clamp technique. Post-CS AF occurred in 53 of 212 patients (25%). Those with post-CS AF were older than those without (67 +/- 2 vs 62 +/- 1 years, P = 0.005). In cells from patients with post-CS AF, the action potential duration at 50% and 90% repolarization, maximum upstroke velocity, and effective refractory period (ERP) were 13 +/- 4 ms, 217 +/- 16 ms, 185 +/- 10 V/s, and 216 +/- 14 ms, respectively (n = 30 cells, 11 patients). Peak L-type Ca(2+) current, transient outward and inward rectifier K(+) currents, and the sustained outward current were -5.0 +/- 0.5, 12.9 +/- 2.4, -4.1 +/- 0.4, and 9.7 +/- 1.0 pA/pF, respectively (13-62 cells, 7-19 patients). None of these values were significantly different in cells from patients without post-CS AF (P > 0.05 for each, 60-279 cells, 29-86 patients), confirmed by multiple and logistic regression. In patients treated >7 days with a beta-blocker pre-CS, the incidence of post-CS AF was lower than in non-beta-blocked patients (13% vs 27%, P = 0.038). Pre-CS beta-blockade was associated with a prolonged pre-CS atrial cellular ERP (P = 0.001), by a similar degree (approximately 20%) in those with and without post-CS AF.
Pre-CS human atrial cellular electrophysiology does not predict post-CS AF. Chronic beta-blocker therapy is associated with a reduced incidence of post-CS AF, unrelated to a pre-CS ERP-prolonging effect of this treatment.
我们研究了心脏手术后(CS)新发房颤(AF)是否可由术前心房细胞电生理学预测,以及β受体阻滞剂治疗的抗心律失常作用是否可能涉及术前药理学重塑。
在CS前,从窦性心律的同意患者中获取心房肌细胞。使用全细胞膜片钳技术记录动作电位和离子电流。212例患者中有53例(25%)发生了CS后房颤。发生CS后房颤的患者比未发生者年龄更大(67±2岁对62±1岁,P = 0.005)。在发生CS后房颤患者的细胞中,复极化50%和90%时的动作电位持续时间、最大上升速度和有效不应期(ERP)分别为13±4毫秒、217±16毫秒、185±10伏/秒和216±14毫秒(n = 30个细胞,11例患者)。L型Ca(2+)电流峰值、瞬时外向和内向整流K(+)电流以及持续外向电流分别为-5.0±0.5、12.9±2.4、-4.1±0.4和9.7±1.0皮安/皮法(13 - 62个细胞,7 - 19例患者)。在未发生CS后房颤患者的细胞中,这些值均无显著差异(每项P > 0.05,60 - 279个细胞,29 - 86例患者),经多元和逻辑回归证实。在术前接受β受体阻滞剂治疗>7天的患者中,CS后房颤的发生率低于未接受β受体阻滞剂治疗的患者(13%对27%,P = 0.038)。术前β受体阻滞剂治疗与术前心房细胞ERP延长相关(P = 0.001),在发生和未发生CS后房颤的患者中程度相似(约20%)。
术前人体心房细胞电生理学不能预测CS后房颤。慢性β受体阻滞剂治疗与CS后房颤发生率降低相关,与该治疗术前延长ERP的作用无关。